Guided Therapeutics Inc (GTHP)

[TheHungryHippo]

Worldwide Licensing, Manufacturing, and Distribution for Luviva

1. CHINA

Guided Therapeutics Inc. granted its current Asian distributor Shenghuo Medical LLC an exclusive license to manufacture, sell, and distribute its LuViva cervical cancer scanning device and related disposables in China and several Southeast Asian countries, including Brunei Darussalam, Cambodia, Laos, Myanmar, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. Shenghuo has been GTI's distributor in China, Hong Kong, and Macau, and the license extends to manufacturing in those countries as well.

CHINA HAS A POTENTIAL 390 MILLION PATIENTS.

All told, Guided Therapeutics said it expects to bring in $47.9 million from the deal over 3 years.

2. TURKEY

Turkish distribution partner ITEM for the manufacture of patented single-patient-use Cervical Guides in Turkey.

In return for the license and manufacturing rights for Cervical Guides in Turkey, the agreement calls for GTHP to receive fees totaling $1,100,000 in 2018, with the first payment due by April 15. In addition, according to the contract, ITEM will pay GTHP a royalty for each Cervical Guide made and sold exclusively in Turkey and ITEM will be obligated to purchase 540 LuViva Advanced Cervical Scans and produce 3,450,000 Cervical Guides for the Turkish market over the next twelve years. The expected minimum revenues for Guided Therapeutics over the twelve-year length of the contract will be approximately $19.4 million, roughly half of which will be product sales and the other half royalty payments, according to the agreement.


3. INDIA

(HOW MUCH MONEY WILL THE INDIA DEAL BE WORTH? THEY ARE SECOND TO CHINA IN TERMS OF # OF POTENTIAL PATIENTS)

Plans for commercialization in world's second most populous country underway

NORCROSS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTCQB:GTHP) reported today that the Company received Regulatory Approval from the Indian Ministry of Health & Family Welfare to allow commercialization of the LuViva device and disposables. The Ministry concluded that the LuViva device is "Non Invasive" and as such is "not regulated under the Drugs and Cosmetics Act 1940 and Medical Device Rules 2017 thereunder." As a result, LuViva can now be commercialized in India.

"There are approximately 330 million women who are age appropriate for cervical cancer screening in India," said Gene Cartwright, CEO. "Only a small percentage of age appropriate women are screened today in India due to the logistical complications of using other methods of cervical cancer screening. LuViva is an attractive alternative because it doesn't require a patient sample or a laboratory, and a result is given in approximately 1 minute at the point of care."

Letter of Intent with DSS Imagetech (DSS) for potential distribution of LuViva in India. DSS is based in New Delhi, has 150 employees and distributes products from Abbott Labs and Olympus. DSS Image has committed to conducting further market research and Guided Therapeutics has committed to further training and travel with the intent of signing a distribution agreement in or before Q2 2018.


4. INDONESIA

"The firm’s LuViva Advanced Cervical scan has recently begun routine use in Indonesia. The Indonesian distributor had made a request for a total of 10 LuViva devices along with four thousand disposables in at the end of last year."

Guided Therapeutics Ships 8 LuViva Devices and 4,500 Single Use Cervical Guides to Indonesia in Q4 2017

GTHP reported today record sales for a quarter in Indonesia, with eight LuViva® Advanced Cervical Scans shipped in the fourth quarter of last year. In addition, Indonesia ordered 4,500 single-use Cervical Guides which were shipped along with the LuViva devices. The increase in orders of high-margin Cervical Guides indicates that installed LuViva units are beginning to see greater usage in hospitals and clinics. Based on previous studies and evaluations of LuViva, medical researchers in Indonesia are recommending the LuViva test as an alternative to the Pap test for cervical cancer screening.


LUVIVA IS ALSO BEING SOLD TO THESE COUNTRIES ALSO!~

Health Canada approved 2012

Singapore Health Authority approved 2012

European CE Mark approved 2013

Mexican COFEPRIS approved 2014

Kenya
Nigeria
Costa Rica
Guatemala
Saudi Arabia
Kuwait
UAE
Chile

There are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer worldwide. The world market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020.


Guided Therapeutics currently has distributors in the following territories:

ASIA:

Afganistan
Azerbaijan
Bangladesh
Georgia
Indonesia
India
Kazakhstan
Korea
Kyrgyzstan
Malaysia
Nigeria
Russia
Slovakia
Tajikistan
Turkmenistan
Uzbekistan

EUROPE:

Armenia
Belgium
Cyprus
Czech Republic
Estonia
Finland
France
Italy
Luxemburg
Netherlands
Turkey
UK

AFRICA:

Algeria
Egypt
Jordan
Kenya
Lebanon
Libya
Malawi
Morocco
Sudan
Tunisia
Uganda

SOUTH AMERICA:

Brazil
Chile
Guatemala

NORTH AMERICA:

Canada
Mexico

MIDDLE EAST:

Iran
Iraq
Saudi Arabia
Kuwait
Oman
Syria
Qatar
UAE
Yemen


http://myluviva.com/intl/distributors-international/
$GTHP